TrialBlood2015

Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma.

Madeleine Duvic et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.